We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
In the latest trading session, Eli Lilly (LLY - Free Report) closed at $263.48, marking a -1.47% move from the previous day. This change lagged the S&P 500's 1.14% loss on the day. Meanwhile, the Dow lost 1.23%, and the Nasdaq, a tech-heavy index, lost 0.36%.
Heading into today, shares of the drugmaker had gained 2.58% over the past month, outpacing the Medical sector's loss of 0.74% and the S&P 500's loss of 1.37% in that time.
Wall Street will be looking for positivity from Eli Lilly as it approaches its next earnings report date. On that day, Eli Lilly is projected to report earnings of $2.37 per share, which would represent a year-over-year decline of 13.82%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.56 billion, up 1.61% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $8.12 per share and revenue of $28.29 billion, which would represent changes of +2.4% and +15.3%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Eli Lilly. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.13% higher. Eli Lilly is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Eli Lilly is currently trading at a Forward P/E ratio of 32.93. For comparison, its industry has an average Forward P/E of 13.85, which means Eli Lilly is trading at a premium to the group.
Meanwhile, LLY's PEG ratio is currently 2.07. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.07 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 115, which puts it in the top 46% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow LLY in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Eli Lilly (LLY - Free Report) closed at $263.48, marking a -1.47% move from the previous day. This change lagged the S&P 500's 1.14% loss on the day. Meanwhile, the Dow lost 1.23%, and the Nasdaq, a tech-heavy index, lost 0.36%.
Heading into today, shares of the drugmaker had gained 2.58% over the past month, outpacing the Medical sector's loss of 0.74% and the S&P 500's loss of 1.37% in that time.
Wall Street will be looking for positivity from Eli Lilly as it approaches its next earnings report date. On that day, Eli Lilly is projected to report earnings of $2.37 per share, which would represent a year-over-year decline of 13.82%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.56 billion, up 1.61% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $8.12 per share and revenue of $28.29 billion, which would represent changes of +2.4% and +15.3%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Eli Lilly. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.13% higher. Eli Lilly is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Eli Lilly is currently trading at a Forward P/E ratio of 32.93. For comparison, its industry has an average Forward P/E of 13.85, which means Eli Lilly is trading at a premium to the group.
Meanwhile, LLY's PEG ratio is currently 2.07. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.07 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 115, which puts it in the top 46% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow LLY in the coming trading sessions, be sure to utilize Zacks.com.